<DOC>
	<DOCNO>NCT03066661</DOCNO>
	<brief_summary>Expanded access entrectinib give patient cancer harbor NTRK1/2/3 , ROS1 , ALK gene fusion qualify participation , otherwise unable access , ongoing clinical trial entrectinib .</brief_summary>
	<brief_title>Expanded Access Entrectinib Cancers With NTRK1/2/3 , ROS1 , ALK Gene Fusions</brief_title>
	<detailed_description />
	<criteria>Diagnosis advance cancer NTRK1 , NTRK2 , NTRK3 , ROS1 , ALK gene fusion Unable participate ongoing entrectinib ( RXDX101 ) clinical trial Willing able provide write , sign informed consent Medically suitable treatment entrectinib ( RXDX101 ) Currently enrol ongoing clinical study investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>